At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m (1) TP).
TOKYO, Aug. 28, 2025 /PRNewswire/ -- Celaid Therapeutics Inc. ("Celaid") have executed a collaborative research agreement with AGC Inc. ("AGC") to advance iPS cell-derived hematopoietic stem and ...
AGC Biologics, your friendly CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc.’s Yokohama Technical Center, marking the ...
AGC (AGC Inc., Headquarters: Tokyo; President: Yoshinori Hirai)(TOKYO:5201), a world-leading manufacturer of glass, chemicals and other high-tech materials, proudly announces the launch of surfactant ...
Ladies and gentlemen, thank you very much for joining us today for Q&A session of AGC's Life Science business. I am Tamaki from PR and IR. It is my pleasure to serve you as [ EMC ]. Let me introduce ...
- Acquisition Will Give AGC Foothold in Europe and Broaden Its Pharma CDMO Business - TOKYO, Dec. 4, 2018 /PRNewswire/ -- AGC Inc., a world-leading manufacturer of glass, chemicals and high-tech ...
The latest announcement is out from AGC ( (JP:5201)). AGC Inc. announced significant changes in its executive leadership, effective January 1, 2026, following a board meeting. These changes involve ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback